

Attorney Docket No.: 4401.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dyrberg et al.

Application No.: 09/872,923

Group Art Unit: 1639

Filed: June 1, 2001

Examiner: Celsa, Bennett M.

For: Treatment of Type I Diabetes

#4
Celsa
9503

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Office communication mailed August 5, 2003, requesting an election of species for purposes of examination. Applicants were requested to elect a single insulin peptide for prosecution on the merits.


Applicants hereby elect AspB25 insulin. Claims 8-15 read on the elected species.

Applicants respectfully request that, upon allowance of a generic claim, additional presently claimed species will be joined.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: September 5, 2003


Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 4401.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dyrberg et al

Serial No.: 09/872,923

Group Art Unit: 1639

Filed: June 1, 2001

Examiner: Celsa, Bennett M.

For: Treatment of Type I Diabetes

**RECEIVED
CENTRAL FAX CENTER**

SEP 05 2003

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Response

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Celsa, Bennett M., fax number (703) 872-9306.

Respectfully submitted,

Date: September 5, 2003


Dolly Kapadia
Novo Nordisk® Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

OFFICIAL